Design Therapeutics Inc DSGN:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 06/03/26 EDT10.44UNCH (UNCH)
Volume
6,148
Close
10.44
+0.27 (+2.65%)
+0.27 (+2.65%)Volume
627,481
52 week range
3.33 - 17.25
- Open10.15
- Day High10.60
- Day Low10.15
- Prev Close10.17
- 52 Week High17.25
- 52 Week High Date04/29/26
- 52 Week Low3.33
- 52 Week Low Date07/01/25
Latest On Design Therapeutics Inc
Key Stats
- Market Cap652.051M
- Shares Out62.46M
- 10 Day Average Volume1.35M
- Dividend-
- Dividend Yield-
- Beta1.66
Latest On Design Therapeutics Inc
KEY STATS
- Open10.15
- Day High10.60
- Day Low10.15
- Prev Close10.17
- 52 Week High17.25
- 52 Week High Date04/29/26
- 52 Week Low3.33
- 52 Week Low Date07/01/25
- Market Cap652.051M
- Shares Out62.46M
- 10 Day Average Volume1.35M
- Dividend-
- Dividend Yield-
- Beta1.66
RATIOS/PROFITABILITY
- EPS (TTM)-1.19
- P/E (TTM)-8.75
- Fwd P/E (NTM)-7.33
- EBITDA (TTM)-78.135M
- ROE (TTM)-31.26%
- Revenue (TTM)-
- Gross Margin (TTM)-
- Net Margin (TTM)-
- Debt To Equity (MRQ)-
EVENTS
- Earnings Date08/05/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREDesign Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN...
Pratik Shah Ph.D.
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Sean Jeffries Ph.D.
Chief Operating Officer
Address
6005 Hidden Valley Road, Suite 110
Carlsbad, CA
92011
United States